OncoMatch/Clinical Trials/NCT06251076
Plan Development for Giving Teclistamab in the Outpatient Setting
Is NCT06251076 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Teclistamab and Tocilizumab for multiple myeloma.
Treatment: Teclistamab · Tocilizumab — This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Multiple Myeloma
Tumor Agnostic
Performance status
ROCKWOOD CLINICAL FRAILTY SCALE 0–5
Prior therapy
Must have received: proteasome inhibitor
Received at least 3 prior lines of therapy, including a proteasome inhibitor
Must have received: immunomodulatory agent
Received at least 3 prior lines of therapy, including ... an immunomodulatory agent
Must have received: anti-CD38 monoclonal antibody
Received at least 3 prior lines of therapy, including ... an anti-CD38 monoclonal antibody
Cannot have received: anti-BCMA therapy (teclistamab)
Prior or concurrent exposure to any of the following: Teclistamab or any anti-BCMA therapy
Cannot have received: other myeloma therapy (standard of care or investigational) including corticosteroids
Exception: within 3 days of first step-up dose of teclistamab
Other myeloma therapy (standard of care or investigational) including corticosteroids, within 3 days of first step-up dose of teclistamab
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06251076 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-BCMA therapy, other myeloma therapy (standard of care or investigational) including corticosteroids disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages